Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of ChronicDiseases Beyond Type 2 Diabetes

W David Strain reports grants and personal fees from Novartis, Boehringer Ingelheim, Pfizer and Novo Nordisk during the conducting of the study. Paivi M Paldanius is an employee and shareholder of Novartis. No other potential conflicts of interest relevant to this article were reported. W David Strain acknowledges the support of the National Institute for Health Research (NIHR) Exeter Clinical Research Facility. The views expressed in this publication are those of the authors and not necessarily those of the NIHR Exeter Clinical Research Facility, the National Health Service, the NIHR, or the Department of Health in England. The publication of this article was supported by Novartis Pharma AG.